Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor

INDIANAPOLIS, November 13 - Eli Lilly and Company (NYSE: LLY) announced today that Steven M. Paul,
M.D., executive vice president, science and technology, and president, Lilly
Research Laboratories, will retire from Lilly effective February 28, 2010.
Lilly has also announced that Jan M. Lundberg, Ph.D., executive vice
president and head of global discovery research, AstraZeneca, is to become
his successor. Paul is committed to working closely with Lundberg to ensure a
successful transition. Lundberg plans to join Lilly in Indianapolis as early
as January 2010, subject to completion of the U.S. immigration process.

Paul joined Lilly as vice president, central nervous system discovery
research and decision-phase medical research, in 1993. He was named group
vice president, therapeutic area discovery research and clinical
investigation, in 1998. Paul has been in his current role since 2003. Before
coming to Lilly, Paul was the scientific director of the National Institute
of Mental Health.

"Under Steve's leadership, we now have the most robust pipeline in
Lilly's history, including approximately 60 unique potential medicines-both
small molecules and biologics-in human testing. Additionally, Steve has
helped to recruit many of the top leaders we have in LRL today. Steve has
also been actively involved in advancing Lilly's research in the area of
Alzheimer's disease, including solanezumab, one of Lilly's two late-stage
Alzheimer's molecules," said John Lechleiter, Ph.D., Lilly chairman and chief
executive officer.

"Steve has also been instrumental in successfully transforming R&D over
the past several years, including the implementation of the FIPNet model,
moving Lilly from a fully integrated pharmaceutical company, where we
previously owned all aspects of the value chain, to a fully integrated
pharmaceutical network, where we are playing bigger than our size. He has
also been a tremendous ambassador for the company, representing Lilly through
his involvement with biopharmaceutical industry, scientific, and medical
organizations," added Lechleiter.

Paul had planned to retire in 2010. With the successful recruitment of
his successor, he will retire at the end of February 2010.

"Advancing our pipeline to patients as quickly and as safely as possible
is the biggest challenge Lilly faces in 2010 and beyond. We are confident
that Dr. Lundberg will be able to deliver on this challenge," said
Lechleiter.

Lundberg has a Ph.D. from Sweden's world-renowned Karolinska Institute,
where he was a professor in the department of pharmacology before moving to
industry. Prior to Karolinska, he attended Gustavus Adolphus College in
Minnesota and the University of Gothenburg in Sweden. He has published
approximately 500 scientific articles, mainly related to mechanisms of cell
signaling in the nervous, cardiovascular, endocrine and respiratory systems.
Lundberg has won a variety of research awards and is a highly cited author in
the areas of biology and biochemistry, pharmacology and neuroscience. He has
been a member of the Swedish Medical Research Council and also of the
Advisory Board for Drug Approvals at the Swedish Medical Product Agency. In
January 2003, he was appointed Honorary Doctor of Pharmacy at Uppsala
University.

During the last 10 years at AstraZeneca, as head of global discovery
research, Lundberg was instrumental in delivering more than 150 drug
candidates to the company's pipeline. He had responsibility for discovery
research and supported clinical development of potential therapies for
cancer, infection, central nervous system disorders, pain, cardiovascular,
metabolic and respiratory diseases, gastrointestinal conditions, and
inflammation. Lundberg was also responsible for discovery-enabling
technologies, discovery informatics, drug metabolism and pharmacokinetics,
translational science and safety assessment. He has had a leading role in
external activities, including in-licensing of projects and technologies, as
well as acquisitions of biotech companies. His organization was involved with
both small molecules and biologics. For the past seven years, he has been an
executive vice president and member of the senior executive team, reporting
to the CEO of AstraZeneca.

"I have always had tremendous respect for the quality of people, science
and products at Lilly. Therefore, I feel honored to be the successor to Steve
Paul. I'm really looking forward to meeting my colleagues at Lilly and
together with them conquering the future challenges and advancing innovative
medicines that meet the needs of patients, payers and prescribers," said
Lundberg.

According to Paul, "Jan possesses the right mix of scientific expertise
and industry experience needed to advance the innovative pipeline of this
company."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information - for some of the world's most urgent
medical needs. Additional information about Lilly is available at
www.lilly.com.

C-LLY

(Logo: www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

Christine Van Marter, Eli Lilly and Company, +1-317-651-1473